September 15 is World Lymphoma Awareness Day, with the theme We Can’t Wait. To honor the leaps and bounds that research into this rare cancer has made, today’s podcast views the current state of lymphoma through different lenses. First, Dr. Constantine Tam, Head of Lymphoma Service at Alfred Hospital and Professor of Hematology at Monash University in Melbourne, Australia talks about the SEQUOIA trial on the efficacy of BTK inhibitor zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukemia and small lymphocytic lymphoma, recently published in Lancet Oncology.
Also, Lorna Warwick, CEO of the Lymphoma Coalition, based in Canada as a federation of more than 80 lymphoma patient organizations worldwide that runs the World Lymphoma Awareness Day project, discusses the more than 80 subtypes of non-Hodgkin’s lymphoma. She has some great insights into the unmet needs of patients with lymphoma and how to budge the needle on care.
Let us know what you thought of this week’s episode on Twitter: @physicianswkly
Want to share your medical expertise, research, or unique experience in medicine on the PW podcast? Email us at firstname.lastname@example.org!
Thanks for listening!